ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

New Leadership at ParaZero Technologies Could Influence Pfizer's Future Strategy

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Bat-Sheva Noy, formerly with Pfizer Israel, has been appointed VP at ParaZero Technologies. Her strategic experience in rare diseases could influence market access strategies relevant to Pfizer, albeit not immediately impactful to PFE&#039;s current valuation.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Former Pfizer executive appointed VP at ParaZero Technologies.</li><li>Bat-Sheva Noy led Rare Diseases at Pfizer Israel until 2025.</li><li>She aims to boost ParaZero&#039;s market presence in drones.</li><li>Noy&#039;s leadership experience is critical for strategic growth.</li><li>No immediate impact on PFE&#039;s core business from this news.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Pfizer Inc. (PFE)</strong>: Noy may leverage her experience for future expansions at Pfizer.</li><li><strong>ParaZero Technologies (PRZO)</strong>: Noy&#039;s strategic focus might lead to competitive innovations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments, relating to leadership changes that affect strategic direction. Noy&#039;s experience may eventually influence Pfizer&#039;s engagement in emerging markets but does not alter the immediate landscape.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Noy&#039;s experience may enhance partnerships that indirectly benefit PFE.</li><li>Potential insights from Noy could refine Pfizer&#039;s disease portfolio strategies.</li><li>Strategic shifts in drone safety may open new market segments for Pfizer.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Bat-Sheva Noy served at Pfizer Israel from 2004 to 2025.</li><li>She managed rare disease operations before joining ParaZero.</li><li>ParaZero focuses on drone safety and aerospace technologies.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Maintain a neutral outlook on PFE in the near term as this news does not directly affect its operations.</p>
  </section>
</section>


<article>
  <h2>ParaZero Technologies Appoints New VP of Global Sales</h2>
  <p>Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/PRZO">PRZO</a>), a leader in aerospace defense, has announced the appointment of Bat-Sheva Noy as its Vice President of Global Sales. This strategic move aims to enhance ParaZero's sales leadership and bolster its presence in the expanding unmanned aerial systems (UAS) market.</p>
  
  <section>
    <h3>Experienced Leadership from Pfizer</h3>
    <p>Ms. Noy brings over 20 years of leadership and commercial experience to ParaZero, particularly in strategic planning and market access. From 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel, a subsidiary of Pfizer Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/quote/PFE">PFE</a>), where she was indispensable in developing and executing business strategies.</p>
    <ul>
      <li>Led teams focused on rare diseases, ensuring strong overall business performance.</li>
      <li>Managed sales and marketing for cardiovascular products from 2017 to 2019 at Pfizer Israel.</li>
      <li>Held various sales and managerial roles at Pfizer from 2004 to 2017.</li>
    </ul>
  </section>
  
  <section>
    <h3>Educational Background and Military Service</h3>
    <p>Bat-Sheva Noy holds an LL.B. in Law from The Academic Centre of Law and Science and a B.Sc. in Chemistry and Biology from Tel Aviv University. Furthermore, she served as an optical systems instructor in the Israel Defense Forces (IDF), showcasing her technical acumen.</p>
  </section>
  
  <section>
    <h3>Strategic Vision for Growth</h3>
    <p>According to ParaZero Technologies, Ms. Noy's profound expertise in leadership and her comprehensive understanding of the market will be vital as the company seeks to expand its global commercial activities in the drone safety and aerospace sector. This growth strategy is timely, given the increasing demand for advanced drone technologies.</p>
  </section>
  
  <section>
    <h3>About ParaZero Technologies</h3>
    <p>Founded in 2014, ParaZero Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/PRZO">PRZO</a>) is at the forefront of aerospace defense, specializing in smart, autonomous solutions for both manned and unmanned systems. The company's robust product lineup includes:</p>
    <ul>
      <li><strong>SafeAir:</strong> An autonomous parachute recovery system aimed at enhancing aerial safety.</li>
      <li><strong>DefendAir:</strong> A counter-UAS platform designed to protect against hostile drones.</li>
      <li><strong>DropAir:</strong> A precision aerial delivery system tailored for various operational needs.</li>
    </ul>
    <p>ParaZero’s mission is to redefine aerial operations by combining intelligence, mission readiness, and safety.</p>
  </section>
  
  <section>
    <h3>Forward-Looking Statements</h3>
    <p>This release contains "forward-looking statements" regarding ParaZero's efforts to expand its global footprint in the aerospace sector. Such statements are based on management's current expectations and are inherently uncertain. Actual results may differ materially from those expressed in these forward-looking statements due to various risk factors.</p>
  </section>
  
  <section>
    <h3>Investor Relations Contact</h3>
    <p>For more information, contact:</p>
    <p>Michal Efraty<br>
      Investor Relations<br>
      <a href="https://www.globenewswire.com/Tracker?data=1reAPEnv4JjxgH7UNfPFM-GyhIZm4hf98vev7TYJ1NkiJbdQJJRsDsftBaf-LEIgy2xX1DSnfvTe2lA_1ZhJB5BEXqrStpDfk08aIslQZz0=" rel="nofollow" target="_blank">michal@efraty.com</a>
    </p>
  </section>
</article>

Bat-Sheva Noy, formerly with Pfizer Israel, has been appointed VP at ParaZero Technologies. Her strategic experience in rare diseases could influence market access strategies relevant to Pfizer, albeit not immediately impactful to PFE's current valuation.

ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News